Standard Immunizations For Children
The national vaccine immunization program, directed principally at children, is one of the most successful examples of effective preventive care in the United States. One of the most dramatic examples of the benefits of appropriate immunization is the marked decrease in cases of invasive Haemophilus influenzae type b (Hib) infection since the introduction of Hib conjugate vaccines (HbCVs) in December 1987. The number of cases in children younger than five years of age declined by >99 percent by 2000. To further emphasize the success of the immunization program, it is important to note the remarkable benefits achieved with recommended administration of the pneumococcal conjugate vaccine.
- Vaccine guidance
- Immunization for travel
- Efficacy for conjugate vaccines
- 4-in-1 pre-school booster
- Vaccines for at risk babies and toddlers
Related Conference of Standard Immunizations For Children
9th International Conference on Vaccines, Immunology and Clinical Trials
7th International conference on Vaccines, Vaccination and Immunization
Standard Immunizations For Children Conference Speakers
Recommended Sessions
- Bacterial Vaccines
- Chicken Pox (Varicella) Vaccines
- Current Research and Future Challenges
- Entrepreneurs Investment Meet
- Flu Vaccines
- Haemophilus Influenza Type b (Hib) Vaccines
- Hepatitis Vaccines
- Human Papillomavirus (HPV) Vaccines
- Immunization safety
- Maternal Immunity
- Meningococcal Vaccines
- Multiple Vaccines (or) Combination Vaccines
- Neonatal Vaccines
- Polio Vaccines
- PPSV (Pneumococcal Vaccines)
- Rotavirus (RV) Vaccines
- Smallpox Vaccines
- Standard Immunizations For Children
- Vaccine Adjuvants
- Vaccine Delivery Technologies
- Vaccine Production and Development
- Vaccine Storage and Handling
- Vaccines For Pregnant Women
Related Journals
Are you interested in
- Adaptive Immunity and Immune Memory Formation - WORLD VACCINES 2026 (France)
- Adjuvants and Immune Modulation Strategies - WORLD VACCINES 2026 (France)
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Adverse reactions to the vaccination - Vaccines Congress-2026 (UK)
- Animal & Plant Derived Vaccines - Vaccines-Immunization-2026 (France)
- Animal Models & Clinical Trials - Vaccines-Immunization-2026 (France)
- Antibodies: Engineering & Therapeutics - Vaccines-Immunization-2026 (France)
- Antinatal vaccinations - Vaccines Congress-2026 (UK)
- Bacterial Vaccines and Toxoid Development - WORLD VACCINES 2026 (France)
- Cancer, Malaria & TB Vaccines - Vaccines-Immunization-2026 (France)
- Cellular Immunology & Latest Innovations - Vaccines-Immunization-2026 (France)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Combination & Conjugate Vaccines - Vaccines-Immunization-2026 (France)
- Computational Immunology and Vaccine Modeling - WORLD VACCINES 2026 (France)
- Conjugated and combination vaccinations - Vaccines Congress-2026 (UK)
- Creation and development of vaccines - Vaccines Congress-2026 (UK)
- Current Research & Future Challenges - Vaccines-Immunization-2026 (France)
- DNA & Synthetic Vaccines - Vaccines-Immunization-2026 (France)
- DNA, RNA & SYNTHETIC VACCINES - Vaccines Congress-2026 (UK)
- Emerging and Re-Emerging Infectious Diseases - WORLD VACCINES 2026 (France)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fish & Poultry Vaccines - Vaccines-Immunization-2026 (France)
- Future Directions in Vaccines and Immunology - WORLD VACCINES 2026 (France)
- Geriatric Immunization - Vaccines-Immunization-2026 (France)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- HIV , Malaria & TB vaccines - Vaccines Congress-2026 (UK)
- HIV Vaccines - Vaccines-Immunization-2026 (France)
- Immunogenetics and Host Immune Variability - WORLD VACCINES 2026 (France)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunopathology and Vaccine Safety - WORLD VACCINES 2026 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Innate Immune Responses in Vaccination - WORLD VACCINES 2026 (France)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- mRNA Vaccines and Nucleic Acid Platforms - WORLD VACCINES 2026 (France)
- Mucosal Immunity and Alternative Vaccine Routes - WORLD VACCINES 2026 (France)
- Paediatric Vaccination - Vaccines-Immunization-2026 (France)
- Pediatric and Geriatric Immunization Strategies - WORLD VACCINES 2026 (France)
- rDNA technology in vaccine development - Vaccines Congress-2026 (UK)
- Recent advances in vaccine development - Vaccines Congress-2026 (UK)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Regulatory Science and Vaccine Approval Pathways - WORLD VACCINES 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- The COVID-19 vaccine's next-generation RNA platforms and mRNA - Vaccines Congress-2026 (UK)
- Toxoid vaccination - Vaccines Congress-2026 (UK)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Translational Vaccinology from Research to Practice - WORLD VACCINES 2026 (France)
- Travel & Edible Vaccines - Vaccines-Immunization-2026 (France)
- Vaccine and Vaccination - Vaccines Congress-2026 (UK)
- Vaccine Biomarkers and Immune Correlates - WORLD VACCINES 2026 (France)
- Vaccine Delivery Systems and Targeting Approaches - WORLD VACCINES 2026 (France)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Design and Antigen Engineering - WORLD VACCINES 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine efficiency and well-being - Vaccines Congress-2026 (UK)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine for infectious illnesses in humans - Vaccines Congress-2026 (UK)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Scale-Up Technologies - WORLD VACCINES 2026 (France)
- Vaccine manufacturing technologies - Vaccines Congress-2026 (UK)
- Vaccine Production & Development - Vaccines-Immunization-2026 (France)
- Vaccine Research and Clinical trials - Vaccines Congress-2026 (UK)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccine-Induced Cellular Immunity - WORLD VACCINES 2026 (France)
- Vaccines - Vaccines-Immunization-2026 (France)
- Vaccines & Autism - Vaccines-Immunization-2026 (France)
- Vaccines against Drugs - Vaccines-Immunization-2026 (France)
- Vaccines against Infectious Diseases - Vaccines-Immunization-2026 (France)
- Vaccines against non-traditional illnesses - Vaccines Congress-2026 (UK)
- VACCINES FOR CANCER - Vaccines Congress-2026 (UK)
- Vaccines for Immune Mediated Diseases - Vaccines-Immunization-2026 (France)
- Vaccines for Pregnant Women & Neonates - Vaccines-Immunization-2026 (France)
- Vaccines for Unconventional Diseases - Vaccines-Immunization-2026 (France)
- Vectors, Adjuvants & Delivery Systems - Vaccines-Immunization-2026 (France)
- Viral Vaccine Platforms and Vector Technologies - WORLD VACCINES 2026 (France)
- Zika Virus vaccines - Vaccines Congress-2026 (UK)

